Australia Anemia in Pregnancy Market

Australia Anemia in Pregnancy Market Insights Forecasts to 2035

• The Australia Anemia in Pregnancy Market Size Was Estimated at USD 190.3 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of Around 9.27% from 2025 to 2035
• The Australia Anemia in Pregnancy Market Size is Expected to Reach USD 504.7 Billion by 2035

According to a research report published by Decisions Advisors, The Australia Anemia in Pregnancy Market Size is Anticipated to Reach USD 504.7 Billion by 2035, growing at a CAGR of 9.27% from 2025 to 2035. The anemia in pregnancy market in Australia is driven by increased awareness of maternal health, government prenatal programs, better diagnoses, and a rise in the incidence of iron deficiency in expectant mothers.

Market Overview

The Anemia in Pregnancy Market pertains to the segment of the health care industry that is involved in the diagnosis, prevention, and treatment of anemia associated with pregnancy. The market includes products such as iron supplements, folate, vitamin B12 formulations, and advanced diagnostic products. The market also includes medical services related to maternal anemia care to improve pregnancy outcomes and reduce complications. The Anemia in Pregnancy Market in Australia is gaining popularity on account of increasing awareness of maternal health, better diagnostics, and prenatal programs supported by the government. The Australian Department of Health endorses regular anemia screening during antenatal visits; in addition, states such as South Australia and Western Australia have developed perinatal anemia management guidelines.

In August 2025, hospitals throughout New South Wales revised their infusion-therapy protocols to include a new procedure for giving ferric carboxymaltose to pregnant patients with moderate to severe iron-deficiency anemia. Market growth is also being supported by the fact that the Pharmaceutical Benefits Scheme (PBS) subsidizes iron supplements, and that there are also national initiatives to address maternal nutrition. Emerging treatment options resulting from technology advancements, including rapid hemoglobin testing and intravenous iron treatments, streamline treatment. Growth opportunities exist in the area of digital prenatal monitoring and enhanced iron supplement formulations.

Report Coverage

This research report categorizes the market for the Australia anemia in pregnancy market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Australia anemia in pregnancy market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Australia anemia in pregnancy market.

Driving Factors

The anemia in pregnancy market in Australia is driven by rising awareness of maternal health, routine antenatal screening programs, and government initiatives that promote nutritional supplementation. The Australian Department of Health recommends hemoglobin testing in early and late pregnancy, which improves diagnosis. The Australian Institute of Health and Welfare (AIHW) reported that approximately 25% of pregnant women experience anemia, making timely intervention critical. Furthermore, the Pharmaceutical Benefits Scheme (PBS) subsidizes iron supplements, which also contributes to market growth.

Restraining Factors

The anemia in pregnancy market in Australia is mostly constrained by side effects of iron supplements or therapies, lack of awareness in rural communities, and the escalating expense of advanced therapies, which all limit uptake and make it difficult to maintain sustained management of anemia in pregnant women.

Market Segmentation

The Australia anemia in pregnancy market share is classified into cause and distribution channel.

• The iron deficiency segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.  

The Australia anemia in pregnancy market is segmented by cause into folic acid deficiency, iron deficiency, vitamin B12 deficiency, and others. Among these, the iron deficiency segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to the fact that iron deficiency, which is caused by insufficient nutritional intake and increased iron demand during pregnancy, is the most frequent cause of anemia in pregnant women. The majority of cases diagnosed in prenatal care are iron-deficiency anemia, according to the Australian Institute of Health and Welfare (AIHW).

• The hospital pharmacy segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.  

The Australia anemia in pregnancy market is segmented by distribution channel into hospital pharmacy, retail pharmacy, online pharmacy, and others. Among these, the hospital pharmacy segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is because the majority of anemia diagnoses and treatments take place in hospital or maternity care settings, when expectant mothers get nutritional support, intravenous iron therapy, and are prescribed iron supplements under physician supervision. Additionally, hospitals manage cases of moderate to severe anemia that necessitate IV iron delivery, increasing sales through hospital pharmacies.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Australia anemia in pregnancy market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Blackmores Limited
• Herbs of Gold Pty Ltd
• Swisse Vitamins Pty Ltd
• Mama Care Group
• Ovitae Pty Ltd
• Pharma Care Laboratories Australia
• AFT Pharmaceuticals Australia Pty Ltd
• Aspen Pharmacare Australia Pty Ltd
• Biostime Australia
• Unrefined Nutrients
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments:

• In June 2025, the researchers of the University of Queensland reported that iron deficiency in pregnancy may change fetal biological sex development; a biological case for maternal iron status.
• In April 2025, the Therapeutic Goods Administration (TGA) reported new safety warnings for parenteral iron products, warning of risks of fetal bradycardia and Kounis syndrome in pregnancy.
• In January 2025, the Walter and Eliza Hall Institute (WEHI) published data from a clinical trial indicating something a single intravenous (IV) iron infusion sometime during late pregnancy significantly increased maternal iron status compared to oral supplementation.

Market Segment

This study forecasts revenue at the Australia, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the Australia anemia in pregnancy market based on the below-mentioned segments:

Australia Anemia in Pregnancy Market, By Cause

• Folic Acid Deficiency
• Iron Deficiency
• Vitamin B12 Deficiency
• Others

Australia Anemia in Pregnancy Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others